Introduction：Basic information about CAS 925432-73-1|SRT 1460, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | SRT 1460 |
|---|
| CAS Number | 925432-73-1 | Molecular Weight | 507.60 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C26H29N5O4S | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 3,4,5-trimethoxy-N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]benzamide |
|---|
| Synonym | More Synonyms |
|---|
SRT 1460 BiologicalActivity
| Description | SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5 > 300 μM), and is more potent than Resveratrol and the closest sirtuin homologues[1]. |
|---|
| Related Catalog | Signaling Pathways >>Epigenetics >>SirtuinResearch Areas >>CancerSignaling Pathways >>Cell Cycle/DNA Damage >>Sirtuin |
|---|
| Target | SIRT1:2.9 μM (EC1.5) |
|---|
| In Vitro | SRT 1460 (2-6 μM; 72 hours) inhibits cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells are: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM[2]. SRT 1460 (5 μM; 16 hours) increases expression of the autophagy marker LC3-II[2]. Cell Viability Assay[2] Cell Line: Patu8988t (pancreatic cancer cells), Panc-1 (pancreatic cancer cells), SU86.86 (pancreatic cancer cells), HPDE cells Concentration: 2 μM, 4 μM, 6 μM Incubation Time: 72 hours Result: Inhibited cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells were: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM. Western Blot Analysis[2] Cell Line: Patu8988t cells Concentration: 5 μM Incubation Time: 16 hours Result: SRT1460 increased expression of the autophagy marker LC3-II. |
|---|
| References | [1]. Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712–716. [2]. Chini CC, et al. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res. 2016 May 15;22(10):2496-507. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Molecular Formula | C26H29N5O4S |
|---|
| Molecular Weight | 507.60 |
|---|
| Exact Mass | 507.194031 |
|---|
| PSA | 117.60000 |
|---|
| LogP | 3.88 |
|---|
| Index of Refraction | 1.669 |
|---|
| InChIKey | SBEWVVLMFLTQFE-UHFFFAOYSA-N |
|---|
| SMILES | COc1cc(C(=O)Nc2ccccc2-c2cn3c(CN4CCNCC4)csc3n2)cc(OC)c1OC |
|---|
Safety Information
| Hazard Codes | Xi |
|---|
| HS Code | 2934100090 |
|---|
Customs
| HS Code | 2934100090 |
|---|
| Summary | 2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
|---|
Synonyms
| 3,4,5-Trimethoxy-N-{2-[3-(1-piperazinylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}benzamide |
| Benzamide, 3,4,5-trimethoxy-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- |
| 3,4,5-trimethoxy-N-{2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}benzamide |
| 3,4,5-trimethoxy-N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)benzamide |
| SRT-1460 |
